ADCY 4 (L226) polyclonal Antibody | BS3421

ADCY 4 (L226) polyclonal Antibody | BS3421 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: Adenylyl cyclases function to convert ATP to cyclic AMP in response to activation by a variety of hormones, neurotransmitters and other regulatory molecules. Cyclic AMP, in turn, activates several other target molecules to control a broad range of diverse phenomena such as metabolism, gene transcription and memory. Adenylyl cyclases respond to receptor-initiated signals, mediated by the Gs and Gi heterotrimeric G proteins. The binding of an agonist to a Gs-coupled receptor catalyzes the exchange of GDP (bound to Gα s) for GTP, the dissociation of GTP-Gα s from Gβγ and Gα s-mediated activation of adenylyl cyclase. Adenylyl cyclase IV (AC IV) and IX mRNA are expressed in all kidney nephron segments. AC IV exhibits moderate staining in type II and type IV fibrocytes in rat cochlea and immunoreactivity is also observed in type I fibrocytes. Activation of the D2 dopaminergic and m4 muscarine receptors inhibits the activity of adenylyl cyclase isozymes I, V, VI and VIII, whereas type II, IV and VII are stimulated and type III is not affected.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: ADCY 4 (L226) polyclonal Antibody detects endogenous levels of Adenylate cyclase type 4 protein.

Molecular Weight: ~ 119 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Adenylate cyclase type 4; ATP pyrophosphate-lyase 4; Adenylate cyclase type IV; Adenylyl cyclase 4; ADCY4; A cyclase IV

Immunogen: Synthetic peptide, corresponding to amino acids 190-240 of Human ADCY 4.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: